伴或不伴脑转移的软脑膜疾病的临床特征与结局:来自柏林夏里特医学院软脑膜疾病登记处的探索性数据分析
该回顾性分析纳入2011至2024年诊断的188例软脑膜疾病患者,评估颅内实质转移与颅外疾病负荷及局部和全身治疗与生存的关系。中位总生存期为2.8个月,诊断后靶向治疗和无脑积水为有利预后因素,诊断前多线全身治疗和缺乏中枢神经系统实质病变增加死亡风险。
要点
- 中位总生存期为2.8个月[95%CI:2.4-3.7]。
- 诊断后靶向治疗(HR:0.33)和无脑积水(HR:0.42)与生存改善独立相关。
- 诊断前≥2线全身治疗增加死亡风险(HR:1.73)。
核心结论
- 无脑积水和诊断后使用靶向治疗是有利的预后因素,而广泛的既往全身治疗和中枢神经系统实质病变使结局恶化。
- 针对颅内疾病的定制治疗对于改善软脑膜疾病患者的生存至关重要。
研究设计与样本
- 对2011年至2024年间诊断的188例软脑膜疾病患者进行回顾性分析。
- 收集人口统计学、影像学发现和治疗数据,采用Kaplan-Meier法进行生存分析,并使用后向逐步Cox回归模型识别独立预后因素。
主要发现
- 原发癌包括乳腺癌(34.0%)、非小细胞肺癌(22.3%)和黑色素瘤(14.4%)。
- 软脑膜疾病通过MRI诊断占56.4%,通过脑脊液细胞学诊断占2.7%,两者均使用占41.0%。
- 中位总生存期为2.8个月[95%CI:2.4-3.7]。
- 改善生存的独立预后因素包括男性(HR:0.61[95%CI:0.40-0.93],p=0.020)、诊断时无脑积水(HR:0.42[95%CI:0.22-0.79],p=0.007)和诊断后靶向治疗(HR:0.33[95%CI:0.20-0.55],p<0.001)。
- 诊断前≥2线全身治疗增加死亡风险(HR:1.73[95%CI:1.16-2.59],p=0.007)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION AND OBJECTIVES: Leptomeningeal disease (LMD) involves disseminating cancer cells to the leptomeninges and cerebrospinal fluid. The impact of intracranial parenchymal brain metastases and extracranial disease burden at LMD diagnosis remains unclear. This study evaluates these factors alongside local and systemic therapies before and after LMD diagnosis. METHODS: A retrospective analysis was conducted on 188 patients diagnosed with LMD between 2011 and 2024. Data on demographics, imaging findings, and treatments were collected. Kaplan-Meier estimates were used for survival analysis, and independent prognostic factors were identified using a backward-stepwise Cox regression model. RESULTS: Primary cancers included breast cancer (34.0%), non-small cell lung cancer (22.3%), and melanoma (14.4%). LMD was diagnosed via MRI in 56.4% of cases, cerebrospinal fluid (CSF) cytology in 2.7%, and both in 41.0%. Median overall survival was 2.8 months [95% CI: 2.4 - 3.7]. Independent prognostic factors for improved survival included male sex (HR: 0.61 [95% CI: 0.40 - 0.93], p = 0.020), absence of hydrocephalus at LMD diagnosis (HR: 0.42 [95% CI: 0.22 - 0.79], p = 0.007), and targeted therapy post-diagnosis (HR: 0.33 [95% CI: 0.20 - 0.55], p < 0.001). Two or more lines of systemic therapy before LMD diagnosis increased mortality risk (HR: 1.73 [95% CI: 1.16 - 2.59], p = 0.007). Lack of CNS parenchymal disease at LMD diagnosis also increased risk (HR: 0.51 [95% CI: 0.30 - 0.89], p = 0.017). Pre-diagnosis radiation therapy showed no survival benefit, while post-diagnosis radiation improved outcomes (HR: 0.47 [95% CI: 0.32 - 0.70], p < 0.001). CONCLUSION: Absence of hydrocephalus and use of targeted therapy post-diagnosis are favorable prognostic factors, while extensive prior systemic therapy and CNS parenchymal disease worsen outcomes. Tailored therapies addressing intracranial disease are crucial for improving survival in LMD patients.
引用
- Wasilewski D, Eitner C, Ates R, et al. Clinical characteristics and outcomes in leptomeningeal disease with or without brain metastasis: insights from an explorative data analysis of the Charité LMD registry. J Neurooncol. 2025. PMID: 39932528. doi:10.1007/s11060-025-04937-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。